KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 71 filers reported holding KALA PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 1.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $242,000 | -58.2% | 175,000 | +11.5% | 0.01% | -37.5% |
| Q4 2019 | $579,000 | -3.0% | 156,900 | 0.0% | 0.01% | 0.0% |
| Q3 2019 | $597,000 | -32.2% | 156,900 | +13.7% | 0.01% | -27.3% |
| Q2 2019 | $880,000 | -22.9% | 138,000 | 0.0% | 0.01% | -21.4% |
| Q1 2019 | $1,141,000 | +174.3% | 138,000 | +62.4% | 0.01% | +133.3% |
| Q4 2018 | $416,000 | -50.4% | 85,000 | 0.0% | 0.01% | -25.0% |
| Q3 2018 | $839,000 | – | 85,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Athyrium Capital Management, LP | 1,333,333 | $5,073,000 | 100.00% |
| CAXTON CORP | 1,483,343 | $5,644,000 | 6.36% |
| Polaris Venture Management Co. V, L.L.C. | 1,197,032 | $4,555,000 | 2.59% |
| RA Capital Management | 4,537,478 | $17,265,000 | 1.03% |
| Orbimed Advisors | 3,447,840 | $13,119,000 | 0.25% |
| Matisse Capital | 46,500 | $177,000 | 0.22% |
| PURA VIDA INVESTMENTS, LLC | 332,831 | $1,266,000 | 0.22% |
| Sofinnova Investments, Inc. | 478,206 | $1,819,000 | 0.16% |
| HARBOURVEST PARTNERS LLC | 99,186 | $377,000 | 0.16% |
| ALGERT GLOBAL LLC | 47,195 | $180,000 | 0.07% |